KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia

Kazushi Fujimoto,Satoshi Ikeda,Erina Tabata, Taichi Kaneko, Shinobu Sagawa, Chieri Yamada, Kosumi Kumagai, Takashi Fukushima, Sanshiro Haga, Masayuki Watanabe,Tatsuya Muraoka,Akimasa Sekine,Tomohisa Baba,Takashi Ogura

Cancers(2024)

引用 0|浏览0
暂无评分
摘要
Non-small-cell lung cancer (NSCLC) with comorbid interstitial pneumonia (IP) is a population with limited treatment options and a poor prognosis. Patients with comorbid IP are at high risk of developing fatal drug-induced pneumonitis, and data on the safety and efficacy of molecularly targeted therapies are lacking. KRAS mutations have been frequently detected in patients with NSCLC with comorbid IP. However, the low detection rate of common driver gene mutations, such as epidermal growth factor receptor and anaplastic lymphoma kinase, in patients with comorbid IP frequently results in inadequate screening for driver mutations, and KRAS mutations may be overlooked. Recently, sotorasib and adagrasib were approved as treatment options for advanced NSCLC with KRASG12C mutations. Although patients with comorbid IP were not excluded from clinical trials of these KRASG12C inhibitors, the incidence of drug-induced pneumonitis was low. Therefore, KRASG12C inhibitors may be a safe and effective treatment option for NSCLC with comorbid IP. This review article discusses the promise and prospects of molecular-targeted therapies, especially KRASG12C inhibitors, for NSCLC with comorbid IP, along with our own clinical experience.
更多
查看译文
关键词
non-small-cell lung cancer,interstitial pneumonia,idiopathic pulmonary fibrosis,acute exacerbation,pneumonitis,cytotoxic drug
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要